Colorectal Cancer

Colorectal Cancer
Pathology
Progression from 1st abnormal cell to CRC
happens over a 10 15 year period.
High risk polyp findings include multiple
polyps, villous polyps, and larger polyps;
Multiple geenetic and environmental
factors have been linked to the
development of CRC.
Information
CRC is a neoplasm that develops in the
colon or rectum.
CRC is the 2nd leading cause of cancer
related deaths and the 3rd most common
cancer.
The life time risk of developing CRC, in the
US, is about 1 in 21 (4.8%)
In 2014, in the US, there were 96,830 new
cases of colon cancer; 40,000 new cases of
rectal cancer.
Diets high in fruits and vegetables have
been linked with decreased risk.
Treatment
Primary Treatment: Surgical resection
Other surgical options include:
hemicolectomy, or colectomy, withnode
resection depending on size and invasion.
Surgery for rectal cancer may include local
transanal, low anterior, or
abdominoperianal resection
Radiation therapy is most often used for
peritoneal or rectal cancers.
1st Line medication: Combination
Chemotherapy which may include
oxaliplatin, irinotecan, fluorouracil,
leucovorin, and capectabine.
2nd line medication: May use along with
1st line medications or alone if 1st line
medications do not work.
Bevacizumab (Avastin) a monoclonal
antibody that targets vascular endothelial
growth factor; inhibits angiogensis.
Cetuximab (Erbitux) and panitumumab
(Vectibix) monoclonal antobodies that
target epidermal growth factor receptors.
Aflibercept and regorafenib are newer
agents with actions on vascular
endothelial growth factor.
Treatment
Primary Treatment: Surgical resection
Other surgical options include:
hemicolectomy, or colectomy, withnode
resection depending on size and invasion.
Surgery for rectal cancer may include local
transanal, low anterior, or
abdominoperianal resection or pelvic
exenteration.
Radiation therapy is most often used for
peritoneal or rectal cancers; it is also used
to relieve symptoms.
1st Line medication: Combination
Chemotherapy which may include
oxaliplatin, irinotecan, fluorouracil,
leucovorin, and capectabine.
2nd line medication: May use along with
1st line medications or alone if 1st line
medications do not work.
Bevacizumab (Avastin) a monoclonal
antibody that targets vascular endothelial
growth factor; inhibits angiogensis.
Cetuximab (Erbitux) and panitumumab
(Vectibix) monoclonal antobodies that
target epidermal growth factor receptors.
Aflibercept and regorafenib are newer
agents with actions on vascular
endothelial growth factor.
109